Related Experiment Videos
Disturbances of lipid metabolism in children with chronic renal failure
1University Children's Hospital, University of Cologne, Germany.
Insights
Children with chronic renal failure often have hyperlipoproteinaemia (HLP), a condition marked by high triglycerides and low HDL cholesterol. Current treatment options for HLP in this population are limited, necessitating further research into safe therapies.
Area of Science:
- Pediatric Nephrology
- Cardiovascular Medicine
- Clinical Biochemistry
Background:
- Children with chronic renal failure frequently exhibit uraemic dyslipidaemia.
- This condition is characterized by hypertriglyceridaemia and reduced high-density lipoprotein-cholesterol (HDL-C).
- Elevated levels of total cholesterol, LDL-C, VLDL-C, and apolipoprotein B are also common.
Purpose of the Study:
- To review the pathogenesis, clinical significance, and current therapeutic strategies for hyperlipoproteinaemia (HLP) in pediatric chronic renal failure.
- To highlight the complex mechanisms underlying dyslipidaemia in these patients.
- To discuss the implications of HLP on cardiovascular health and renal disease progression.
Main Methods:
- Literature review focusing on pathogenesis, clinical impact, and treatment of HLP in pediatric chronic renal failure.
- Analysis of lipid profiles, including triglycerides, HDL-C, LDL-C, and lipoprotein(a).
- Discussion of pathophysiological mechanisms and their relation to cardiovascular risk and renal disease.
Main Results:
- The majority of patients with chronic renal failure present with uraemic dyslipidaemia, including hypertriglyceridaemia and low HDL-C.
- Elevated levels of total cholesterol, LDL-C, VLDL-C, apolipoprotein B, and lipoprotein(a) are frequently observed.
- Diminished catabolism of triglyceride-rich lipoproteins is a primary pathophysiological mechanism.
Conclusions:
- HLP significantly contributes to cardiovascular morbidity and mortality in children with chronic renal failure.
- Dyslipidaemia may accelerate renal disease progression in patients with residual renal function.
- Limited data exists on the safety and efficacy of lipid-lowering drugs in this pediatric population, restricting pharmacological treatment recommendations.
Abstract:
This review discusses the pathogenesis, clinical significance and current therapy of hyperlipoproteinaemia (HLP) in children with chronic renal failure. Uraemic dyslipidaemia, characterized by hypertriglyceridaemia and low high-density lipoprotein-cholesterol levels, is present in the majority patients with chronic renal failure. In addition, serum levels of total cholesterol, very low-density lipoprotein-cholesterol, low-density lipoportein-cholesterol and apolipoprotein B are frequently elevated. The pathophysiological mechanisms causing these disturbances are complex and mainly involve a diminished catabolism of triglyceride-rich lipoproteins. For unknown reasons and independent of other lipoproteins, serum levels of the highly atherogenic and thrombogenic lipoprotein(a) are also often elevated. HLP is an important factor in cardiovascular morbidity and mortality. In addition, dyslipidaemia may enhance progression of renal disease in patients with residual renal function. Therefore, treatment of HLP seems indicated in overtly hyperlipidaemic patients, but until there is more experience with lipid-lowering drugs in children, no safe recommendations for pharmacological treatment of HLP can be given. Dietary modifications can be recommended only to a limited extent.